Association of APOB (rs515135) and PCSK9 (rs505151) gene polymorphisms with CAD in the Indian population.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI:10.1080/17520363.2025.2496128

Ale Eba, Syed Tasleem Raza, Irshad Ahmad Wani, Bashir Ahmad, Mohammad Abbas, Zeba Siddiqi, Sanchita Srivastava, Farzana Mahdi

{"title":"Association of APOB (rs515135) and PCSK9 (rs505151) gene polymorphisms with CAD in the Indian population.","authors":"Ale Eba, Syed Tasleem Raza, Irshad Ahmad Wani, Bashir Ahmad, Mohammad Abbas, Zeba Siddiqi, Sanchita Srivastava, Farzana Mahdi","doi":"10.1080/17520363.2025.2496128","DOIUrl":null,"url":null,"abstract":"Introduction: Coronary artery disease (CAD) is a multifactorial disorder influenced by both genetic and clinical risk factors. Lipid metabolism genes such as apolipoprotein B(APOB) (rs515135) and proprotein convertase subtilisin/kexin type 9 (PCSK9)(rs505151), have been associated with susceptibility to CAD. Study investigates the potential role of these genetic polymorphisms with risk of CAD in the Indian population.Materials and methods: A case-control study including 150 CAD cases and 150 controls. Angiographically proven Cases were recruited from the Cardiology Unit, Department of Medicine, Era's Lucknow Medical College. Genotyping was done using specific primers and restriction digestion; statistical analysis included t-tests, odds ratios, and haplotype analysis.Results: CAD cases(mean age 49.93 ± 9.13 years) had higher serum cholesterol and VLDL but lower systolic and diastolic BP compared to controls (mean age 56.47 ± 9.39 years). The APOB G allele showed a significant protective effect against CAD (OR: 0.431,p = 0.001).Conclusion: The APOB G allele may serve as a protective factor against CAD, highlighting its potential role in genetic screening for lower disease risk. Further large-scale studies are required to confirm these findings.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 10","pages":"371-377"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077466/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2496128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Coronary artery disease (CAD) is a multifactorial disorder influenced by both genetic and clinical risk factors. Lipid metabolism genes such as apolipoprotein B(APOB) (rs515135) and proprotein convertase subtilisin/kexin type 9 (PCSK9)(rs505151), have been associated with susceptibility to CAD. Study investigates the potential role of these genetic polymorphisms with risk of CAD in the Indian population.

Materials and methods: A case-control study including 150 CAD cases and 150 controls. Angiographically proven Cases were recruited from the Cardiology Unit, Department of Medicine, Era's Lucknow Medical College. Genotyping was done using specific primers and restriction digestion; statistical analysis included t-tests, odds ratios, and haplotype analysis.

Results: CAD cases(mean age 49.93 ± 9.13 years) had higher serum cholesterol and VLDL but lower systolic and diastolic BP compared to controls (mean age 56.47 ± 9.39 years). The APOB G allele showed a significant protective effect against CAD (OR: 0.431,p = 0.001).

Conclusion: The APOB G allele may serve as a protective factor against CAD, highlighting its potential role in genetic screening for lower disease risk. Further large-scale studies are required to confirm these findings.

查看原文本刊更多论文

APOB （rss515135）和PCSK9 （rs505151）基因多态性与CAD在印度人群中的关联

简介：冠状动脉疾病（CAD）是一种受遗传和临床危险因素影响的多因素疾病。脂质代谢基因如载脂蛋白B(APOB) （rss515135）和蛋白转化酶枯草杆菌素/酮素9型（PCSK9）（rs505151）与CAD易感性相关。研究调查了这些基因多态性与冠心病风险在印度人群中的潜在作用。材料与方法：病例-对照研究，包括150例CAD病例和150例对照。血管造影证实的病例来自Era's勒克瑙医学院医学系心脏病科。采用特异性引物和限制性酶切法进行基因分型；统计分析包括t检验、优势比和单倍型分析。结果：冠心病患者（平均年龄49.93±9.13岁）血清胆固醇和VLDL高于对照组（平均年龄56.47±9.39岁），收缩压和舒张压低于对照组（平均年龄56.47±9.39岁）。APOB G等位基因对冠心病有显著的保护作用（OR: 0.431,p = 0.001）。结论：APOB G等位基因可能是CAD的保护因子，在降低疾病风险的遗传筛查中具有潜在作用。需要进一步的大规模研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.